Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Synovitis, Pigmented Villonodular 1Stage I Prostate Adenocarcinoma 1Solid Tumors 1Solid Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Advanced Solid Tumors 1

Interventions

Imatinib Mesylate 12Sunitinib 4Leucovorin 3ripretinib 2nilotinib 2avapritinib 2Oxaliplatin 2Irinotecan 2Ipilimumab 2Fluorouracil 2CTLA-4 Antigen 2umbralisib 1tanespimycin 1spartalizumab 1sargramostim 1ribociclib 1repaglinide 1regorafenib 1pexidartinib 1olverembatinib 1binimetinib 1alvocidib 1Thalidomide 1TH 302 1TAS-116 1Pharmacogenomic Testing 1OSI 930 1Midazolam 1IDRX-42 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Stromal Tumors × pexidartinib × Clear all
NCT03158103 2021-04-30

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
3 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡